Двусторонняя адреналэктомия в XXI веке, ее роль при гиперкортицизме? (обзор литературы)
https://doi.org/10.25694/URMJ.2018.04.074
Аннотация
Актуальность. В последние годы значительно увеличилось число операций, проводимых на надпочечниках. Это связано также с улучшением методов диагностики различного рода патологий этих желез и увеличило цифры распространенности заболеваний надпочечников в общей популяции. Цель обзора: 1) выявление потенциальных показаний к двусторонней адреналэктомии (ДА) в условиях обновленных терапевтических алгоритмах СК; 2) сравнить эффективность и побочные эффекты различных терапевтических вариантов лечения гиперкортицизма с результатами двусторонней ДА, чтобы лучше определить показания к ней в 21 веке. Материалы и методы. Поиск литературы с поисковым термином: «двусторонняя адреналэктомия». Источник: PubMed, Medline. результаты. обзор 174 просмотренных публикаций, симптомы гиперкортицизма (гипертония, ожирение и депрессия) улучшились у большинства пациентов после ДА (7 исследований, 195 пациентов). Примерно 46% пациентов умерли в первый год после операции. Вывод. Изучить влияние ДА, ее своевременность в лечении пациентов.
Об авторах
Т. П. Киселева
ФГБОУ ВО «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
Т. Р. Чжен
ФГБОУ ВО «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
М. Р. Торосян
ФГБОУ ВО «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
Список литературы
1. Drougat L., Omeiri H., Lefèvre L. Novel Insights into the Genetics and Pathophysiology of Adrenocortical Tumors. Front Endocrinol (Lausanne). 2015; 6: 96. DOI: 10.3389/fendo.2015.00096
2. Lieberman S.A., Eccleshall T.R., Feldman D: ACTH-independent massive bilateral adrenal disease (AIMBAD): A subtype of Cushing’s syndrome with major diagnostic and therapeutic implications. Eur J Endocrinol 1994; 131: 67-73. DOI: 10.1530/eje.0.1310067 • Source: PubMed
3. Stratakis C.A., Kirschner L.S.: Clinical and genetic analysis of primary bilateral adrenal diseases (micro-and macronodular disease) leading to Cushing syndrome. Horm Metab Res 1998; 30: 456-463. DOI: 10.1055/s-2007-978914
4. Swain J.M., Grant C.S., Schlinkert R.T., Thompson G.B., van Heerden J.A., Lloyd R.V., Young W.F.: Corticotropin-independent macronodular adrenal hyperplasia: A clinicopathologic correlation. Arch Surg 1998; 133: 541-545. doi: 10.1001/archsurg.133.5.541
5. Malchoff C.D., MacGillivray D., Malchoff D.M.: Adrenocorticotropic hormone-independent adrenal hyperplasia. Endocrinologist 1996; 6: 79-85.
6. Zeiger M.A., Nieman L.K., Cutler G.B., Chrousos G.P., Doppman J.L., Travis W.D., Norton J.A.: Primary bilateral adrenocortical causes of Cushing ’s syndrome. Surgery 1991; 110: 1106-1115.
7. Aiba M., Hirayama A., Iri H., Ito Y., Fujimoto Y., Mabuchi G., Murai M., Tazaki H., Maruyama H., Saruta T: Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia as a distinct subtype of Cushing ’s syndrome. Enzyme histochemical and ultrastructural study of four cases with a review of the literature. Am J Clin Pathol 1991; 96: 334-340. https://doi.org/10.1093/ajcp/96.3.334
8. Lacroix A., N’Diaye N., Tremblay J., Hamet P: Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr Rev 2001; 22: 75-110. DOI: 10.1210/edrv.22.1.0420
9. Minami S., Sugihara H., Sato J., Tatsukuchi A., Sugisaki Y., Sasano H., Wakabayashi I.: ACTH independent Cushing’s syndrome occurring in siblings. Clin Endocrinol (Oxf) 1996; 44: 483-488.https://doi.org/10.1046/j.1365-2265.1996.682504.x
10. Nies C., Bartsch D.K., Ehlenz K., Wild A., Langer P., Fleischhacker S., Rothmund M: Familial ACTH-independent Cushing’s syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members. Exp Clin Endocrinol Diabetes 2002; 110: 277-283. DOI: 10.1055/s-2002-34590
11. Findlay J.C., Sheeler L.R., Engeland W.C., Aron DC: Familial adrenocorticotropin-independent Cushing’s syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1993; 76: 189-191. DOI: 10.1210/jcem.76.1.8380604
12. Imohl M., Koditz R., Stachon A., Muller KM, Nicolas V., Pfeilschifter J., Krieg M: Catecholamine-dependent hereditary Cushing’s syndrome - Follow-up after unilateral adrenalectomy (in German). Med Klin (Munich) 2002; 97: 747-753.
13. Lee S., Jun S., Hong SW, Kim D.J., Rhee Y., Lim SK: Familial adrenocorticotropin-independent macronodular adrenal hyperplasia: Ectopic expression of vasopressin V1b, V2 receptors in the adrenal gland (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 566.
14. Kirschner M.A., Powell RD J.R., Lipsett M.B.: Cushing’s syndrome: Nodular cortical hyperplasia of adrenal glands with clinical and pathological features suggesting adrenocortical tumor. J Clin Endocrinol Metab 1964; 24: 947- 955. DOI: 10.1210/jcem-24-10-947
15. Else T., Kim A.C., Sabolch A., Raymond V.M., Kandathil A., Caoili E.M. et al. Adrenocortical carcinoma. Endocr Rev (2014) 35: 282-326. Doi: 10.1210/er.2013-1029 [PMC free article] [PubMed] [Cross Ref]
16. Abiven G., Coste J., Groussin L., Anract P., Tissier F., Legmann P., et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab (2006) 91: 2650-5 https://doi.org/10.1210/jc.2005-2730 [PubMed][Cross Ref]
17. Allolio B., Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab (2006) 91: 2027-37 https://doi.org/10.1210/jc.2005-2639 [PubMed] [Cross Ref]
18. Libè R., Fratticci A., Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer (2007) 14: 13-28. Doi: 10.1677/ erc.1.01130 [PubMed] [Cross Ref]
19. Luton J.P., Cerdas S., Billaud L., Thomas G., Guilhaume B., Bertagna X., et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med (1990) 322: 1195-201. Doi: 10.1056/NEJM199004263221705 [PubMed] [Cross Ref]
20. Assie G., et al. 2013 ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. New England Journal of Medicine 369 2105-2114. doi: 10.1056/NEJMoa1304603. CrossRef MedlineWeb of Science. Google Scholar.
21. Louiset E., et al. 2013 Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. New England Journal of Medicine 369 2115-2125. doi: 10.1056/NEJMoa1215245. CrossRefMedlineWeb of ScienceGoogle Scholar.
22. Bertherat J. 2006 Carney complex (CNC). Orphanet Journal of Rare Diseases 1 21. doi: 10.1186/1750-1172-1-21. CrossRef. Medline. Google Scholar.
23. Feelders R.A., Hofland L.J. Medical treatment of Cushing's disease. J Clin Endocrinol Metab. 2013; 98: 425-438. DOI: 10.1210/jc.2012-3126 Google Scholar. CrossRef. PubMed
24. Colao A., Petersenn S., Newell-Price J., et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med.2012; 366: 914-924. DOI: 10.1056/ NEJMoa1105743 Google Scholar. CrossRef. PubMed.
25. Nieman L.K., et al. 2015 Treatment of Cushing's syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 100 2807-2831. doi: 10.1210/jc.2015-1818. CrossRef. Medline. Google Scholar.
26. Lacroix A., et al. 2015 Cushing's syndrome.Lancet 386 913-927. doi: 10.1016/S0140-6736(14)61375-1. Cross Ref. Medline. Google Scholar.
27. Plotz C.M., Knowlton A.I., Ragan C. The natural history of Cushing's syndrome. Am J Med. 1952; 13: 597-614. DOI: https://doi.org/10.1016/0002-9343(52)90027-2 Google Scholar. CrossRef. PubMed.
28. Lindholm J., Juul S., Jørgensen J.O., et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001; 86: 117- DOI: 10.1210/jcem.86.1.7093 Google Scholar. PubMed.
29. Bolland M.J., Holdaway I.M., Berkeley J.E., et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf). 2011; 75: 436-442. DOI: 10.1111/j.1365-2265.2011.04124.x Google Scholar. CrossRef. PubMed.
30. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994; 40: 479-484. https://doi.org/10.1111/j.1365-2265.1994.tb02486.x Google Scholar. CrossRef. PubMed.
31. Dekkers O.M., Biermasz N.R., Pereira A.M., et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007; 92: 976-981. DOI: 10.1210/jc.2006-2112 Google Scholar. CrossRef. PubMed.
32. Clayton R.N., Raskauskiene D., Reulen R.C., Jones P.W. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Meta. 2011; 96: 632-642. DOI: 10.1210/jc.2010-1942 Google Scholar. CrossRef. PubMed.
33. Graversen D., Vestergaard P., Stochholm K., Gravholt C.H., Jørgensen J.O. Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012; 23: 278-282. DOI: 10.1016/j.ejim.2011.10.013 Google Scholar. CrossRef. PubMed.
34. Hammer G.D., Tyrrell J.B., Lamborn K.R., et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004; 89: 6348-6357. DOI: 10.1210/jc.2003-032180 Google Scholar. CrossRef. PubMed.
35. Swearingen B., Biller B.M.,Barker F.G 2nd et al. Longterm mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999; 130: 821-824. DOI: 10.7326/0003-4819-130-10-199905180-00015 Google Scholar. CrossRef. PubMed.
36. Walz M.K., Peitgen K., Hoermann R. et al. Posterior retroperitoneoscopy as a new minimally invasive approach for adrenalectomy: results of 30 adrenalectomies in 27 patients. World J Surg 1996; 769-774. DOI: 10.1007/s002689900117 [PubMed]
37. Yadav K., Bakshi G., Prakash G. et al. Simultaneous bilateral laparoscopic adrenalectomy for pheochromocytoma in multiple endocrine neoplasia (MEN) syndrome: case report with review literature. Int J Surg Case Rep 2014;: 487-490. doi: 10.1016/j.ijscr.2014.03.007 [PMC free article][PubMed]
38. Constantinides V.A., Christakis I., Touska P. et al. Systematic review and meta-analysis of retroperitoneoscopic versus laparoscopic adrenalectomy. Br J Surg 2012;: 1,639-1,648. DOI: 10.1002/bjs.8921
39. Dindo D., Demartines N., Clavien P.A. Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;: 205-213. doi: 10.1097/01. sla.0000133083.54934.ae [PMC free article] [PubMed]
40. O Riordain D.S., Farley D.R., Young W.F. et al. Long term out-come of bilateral adrenalectomy in patients with Cushings syndrome. Surgery. 1994 Dec; 116(6): 1088-93; discussion 1093-4.
41. Takata M.C., Kebebew E., Clark O.H. et al. Laparoscopic bilateral adrenalectomy: results for 30 consecutive cases. Surg Endosc 2008;: 202-207. DOI: 10.1007/ s00464-007-9478-3 [PubMed]
42. Chow J.T., Thompson G.B., Grant C.S. et al. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing s syndrome: a review of the Mayo clinic experience. Clin Endocrinol (Oxf). 2008 Apr; 68(4): 513-9. DOI: 10.1111/j.1365-2265.2007.03082.x
43. Walz M.K., Alesina P.F., Wenger F.A. et al. Posterior retroperitoneoscopic adrenalectomy: results of 560 procedures in 520 patients. Surgery. 2006 Dec; 140(6): 943-8; discussion 948-50. DOI: 10.1016/j.surg.2006.07.039 [PubMed]
44. Lombardi C.P., Raffaelli M., De Crea C. et al. Endoscopic adrenalectomy: is there an optimal operative approach? Results of a single-center case-control study. Surgery. 2008 Dec; 144(6): 1008-14; discussion 1014-5. doi: 10.1016/j.surg.2008.08.025. [PubMed]
45. Miccoli P., Materazzi G., Brauckhoff M. et al. No outcome differences between a laparoscopic and retroperitoneoscopic approach in synchronous bilateral adrenal surgery. World J Surg. 2011 Dec; 35(12): 2698-702. doi: 10.1007/s00268-011-1294-1. [PubMed]
46. Raffaelli M., Brunaud L., De Crea C. et al. Synchronous bilateral adrenalectomy for Cushing s syndrome: laparoscopic versus posterior retroperitoneoscopic versus robotic approach. World J Surg 2014: 709-715. DOI: 10.1007/s00268-013-2326-9 [PubMed]
47. Ramacciato G., Nigri G.R., Petrucciani N et al. Minimally invasive adrenalectomy: a multicenter comparison of transperitoneal and retroperitoneal approaches. Am Surg 2011;: 409-416. https://www.ncbi.nlm.nih.gov/pubmed/21679547
48. Gumbs A.A., Gagner M. Laparoscopic adrenalectomy. Best Pract Res Best Pract Res Clin Endocrinol Metab. 2006 Sep; 20(3): 483-99. DOI: 10.1016/j.beem.2006.07.010 [PubMed]
49. Ritzel K., Beuschlein F., Mickisch A. et al. Clinical review: outcome of bilateral adrenalectomy in Cushing s syndrome: a systematic review. J Clin Endocrinol Metab. 2013 Oct; 98(10): 3939-48. doi: 10.1210/jc.2013-1470. Epub 2013 Aug 16. [PubMed]
50. Young H. (1936) Technique for simultaneous exposure and operation on adrenals. Surgery 63 119. Google Scholar
51. Russell C.F., ey al. 1982Adrenalectomy: anterior or posterior approach? American Journal of Surgery 144322-324. doi: 10.1016/0002-9610(82)90010-1. Cross Ref MedlineWeb of Science Google Scholar
52. Gagner M., Lacroix A., Bolte E. 1992 Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. New England Journal of Medicine 327 1033. doi: 10.1056/NEJM199210013271417. Cross Ref Medline Web of Science Google Scholar
53. Ritzel K., Reincke M. et al. 2013 Clinical Review: Outcome of bilateral adrenalectomy in Cushing's syndrome: a systematic review. Journal of Clinical Endocrinology and Metabolism 983939-3948. doi: 10.1210/jc.2013-1470. Cross Ref Medline Web of Science Google Scholar
54. Reincke M., et al. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. European Journal of Endocrinology 2015; 173 M23-M32. doi: 10.1530/EJE-15-0265. Abstract/ FREE Full Text.
55. Sharma R., et al. Laparoscopic management of adrenal lesions larger than 5 cm in diameter. Urology Journal 2009; 6(4): 254-259. Medline Google Scholar
56. Miccoli P., et al. No outcome differences between a laparoscopic and retroperitoneoscopic approach in synchronous bilateral adrenal surgery. World Journal of Surgery. 2011; 35 2698-2702. doi: 10.1007/s00268-011-1294-1. Cross Ref Medline Google Scholar
57. Lan B.Y. et al. Factors affecting the surgical approach and timing of bilateral adrenalectomy. Surgical Endoscopy 2015; 29 1741-1745. doi: 10.1007/s00464-014-3891-1.Cross Ref Medline Google Scholar
58. Raffaelli M., et al. Synchronous bilateral adrenalectomy for Cushing's syndrome: laparoscopic versus posterior retroperitoneoscopic versus robotic approach. World Journal of Surgery 2014; 38 709-715. doi: 10.1007/ s00268-013-2326-9. Cross Ref Medline Google Scholar
59. Nieman L.K., et al. Treatment of Cushing's syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2015; 100 2807-2831. doi: 10.1210/jc.2015-1818.Cross Ref Medline Google Scholar.
60. Ntali G., et al. Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. European Journal of Endocrinology 2013; 169 715-723. doi: 10.1530/EJE-13-0569. Abstract/ FREE Full Text.
61. Andela C.D., et al. Mechanisms in Endocrinology: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. European Journal of Endocrinology 2015; 173 R1-14. doi: 10.1530/EJE-14-1101. Abstract/FREE Full Text.
62. Bertagna X. & Guignat L. Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery. Journal of Clinical Endocrinology and Metabolism 2013; 98 1307-1318. doi: 10.1210/jc.2012-3200. Cross Ref Medline Web of Science Google Scholar.
63. Osswald A., et al. Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. European Journal of Endocrinology 2014; 171209-215. doi: 10.1530/EJE-14-0214. Abstract/FREE Full Text.
64. Katznelson LBilateral adrenalectomy for Cushing's disease. Pituitary. 2015; 18 269-273. doi: 10.1007/ s11102-014-0633-2. Cross Ref Medline Google Scholar.
65. Neychev V., et al. Long-term outcome of bilateral laparoscopic adrenalectomy measured by disease-specific questionnaire in a unique group of patients with Cushing's syndrome. Annals of Surgical Oncology 2015; 22 (Suppl 3) 699-706. doi: 10.1245/s10434-015-4605-1. Cross Ref Medline Google Scholar.
66. Wong A., Eloy J.A., Liu J.K. The role of bilateral adrenalectomy in the treatment of refractory Cushing's disease. Neurosurgical 2015; Focus 38 E9. doi: 10.3171/2014.10.FOCUS14684. Google Scholar.
67. Corcuff J.B., et al. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology 2015; 172 4 73481. doi: 10.1530/EJE-14-0913. Abstract/FREE Full Text.
68. Kamenicky P., et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2011; 96 2796-2804. doi: 10.1210/jc.2011-0536. Cross Ref Medline Web of Science Google Scholar.
69. Fleseriu M., et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2012; 97 2039-2049. doi: 10.1210/jc.2011-3350. Cross Ref MedlineWeb of Science Google Scholar.
70. Castinetti F., et al. Merits and pitfalls of mifepristone in Cushing's syndrome. European Journal of Endocrinology 2009; 160 1003-1010. doi: 10.1530/EJE-09-0098. Abstract/FREE Full Text.
71. Castinetti F., Brue T & Conte-Devolx B. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. Current Opinion in Endocrinology, Diabetes, and Obesity 2012; 19 295-299. doi: 10.1097/MED.0b013e32835430bf Cross Ref Google Scholar.
72. Preda V.A., et al. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. European Journal of Endocrinology 2012; 167 137143. doi: 10.1530/EJE-12-0274. Abstract/FREE Full Text.
73. Pivonello R., et al. The treatment of Cushing's disease. Endocrine Reviews. 2015; 36 385-486. doi: 10.1210/er.2013-1048. Cross Ref Medline Google Scholar.
74. Petersenn S., at al. High variability in baseline urinary free cortisol values in patients with Cushing's disease. Clinical Endocrinology 2014; 80 261-269. doi: 10.1111/cen.12259. Cross Ref Medline Google Scholar.
75. Sippel R.S., et al. Waiting for change: symptom resolution after adrenalectomy for Cushing's syndrome. Surgery 2008; 144 1054-1060; discussion 1060-1051. doi: 10.1016/j.surg.2008.08.024. Cross Ref Medline Web of Science Google Scholar.
76. Chow JT, et al. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clinical Endocrinology 2008; 68 513-519. doi: 10.1111/j.1365-2265.2007.03082.x.CrossRefMedline Google Scholar.
77. Osswald A., et al. Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. European Journal of Endocrinology 2014; 171209-215. doi: 10.1530/EJE-14-0214. Abstract/FREE Full Text.
78. Nagesser S.K. et al. Long-term results of total adrenalectomy for Cushing's disease. World Journal of Surgery 2000; 24 108-113. doi: 10.1007/s002689910020. Cross Ref Medline Web of Science Google Scholar.
79. Kemink L., et al. Residual adrenocortical function after bilateral adrenalectomy for pituitary-dependent Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1992; 75 1211-1214. DOI: 10.1210/jcem.75.5.1331164 Cross Ref Medline Web of Science Google Scholar
80. Chalmers R.A., Mashiter K., Joplin G.F. Residual adrenocortical function after bilateral "total" adrenalectomy for Cushing's disease. Lancet 1981; 2 1196-1199. doi: 10.1016/S0140-6736(81)91438-0. Medline Google Scholar.
81. Assie G., et al. Prognostic parameters of metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2007; 92148-154. doi: 10.1210/jc.2006-0706.CrossRef Medline Web of Science Google Scholar.
82. Azad TD, et al. Nelson syndrome: update on therapeutic approaches. World Neurosurgery 2015; 83 1135-1140. doi: 10.1016/j.wneu.2015.01.038. Cross Ref Medline Google Scholar.
83. Husebye ES, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency Journal of Internal Medicine 2014; 275 104-115. doi: 10.1111/joim.12162. Cross Ref Medline Google Scholar.
84. Hahner S., et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. Journal of Clinical Endocrinology and Metabolism 2015; 100 407-416. doi: 10.1210/jc.2014-3191. Cross Ref Medline Google Scholar.
85. Colao A., et al. A 12-month phase 3 study of pasireotide in Cushing's disease. New England Journal of Medicine 2012; 366 914-924. doi: 10.1056/NEJMoa1105743. Cross Ref Medline Web of Science Google Scholar.
86. Pivonello R., et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. Clinical Endocrinology 2014; 81 408-417. doi: 10.1111/cen.12431. Cross Ref Medline Google Scholar.
87. Petrossians P., Thonnard A.S., Beckers A. Medical treatment in Cushing's syndrome: dopamine agonists and cabergoline. Neuroendocrinology 2010; 92 (Suppl 1)116-119. doi: 10.1159/000317716. Cross Ref Medline Google Scholar.
88. Baudry C., et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. European Journal of Endocrinology 2012; 167 473481. doi: 10.1530/EJE-12-0358. Abstract/FREE Full Text.
89. Castinetti F., et al. Ketoconazole in Cushing's disease: is it worth a try? Journal of Clinical Endocrinology and Metabolism 2014; 99 1623-1630. doi: 10.1210/jc.2013-3628. Cross Ref Medline Web of Science Google Scholar.
90. Daniel E., et al. Effectiveness of metyrapone in treating Cushing's Syndrome: a retrospective multicenter study in 195 patients. Journal of Clinical Endocrinology and Metabolism 2015; 100 4146-4154. doi: 10.1210/ jc.2015-2616. Cross Ref Medline Google Scholar.
91. Alexandraki K.I. & Grossman A.B. The ectopic ACTH syndrome. Reviews in Endocrine & Metabolic Disorders. 2010; 11 117-126. doi: 10.1007/s11154-010-9139-z. Cross Ref Medline Web of Science Google Scholar.
92. Tabarin A., et al. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. Journal of Clinical Endocrinology and Metabolism 1999; 84 1193-1202. doi: 10.1210/jcem.84.4.5583. Cross Ref Medline Web of Science Google Scholar.
93. Torpy D.J., et al. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. Journal of Clinical Endocrinology and Metabolism 1999; 84 1186-1192. doi: 10.1210/jcem.84.4.5576. Cross Ref Medline Web of Science Google Scholar.
94. de Herder W.W. et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. American Journal of Medicine 1994; 96 305312. doi: 10.1016/0002-9343(94)90059-0. Cross Ref Medline Web of Science Google Scholar.
95. Phlipponneau M., et al. Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. Journal of Clinical Endocrinology and Metabolism. 1994 Jan; 78(1): 20-4. DOI: 10.1210/jcem.78.1.7904613 Cross Ref Medline Web of Science Google Scholar.
96. Rufini V., Calcagni M.L & Baum R.P. Imaging of neuroendocrine tumors. Seminars in Nuclear Medicine 2006; 36 228-247. doi: 10.1053/j.semnuclmed.2006.03.007. Cross Ref Medline Google Scholar.
97. Santhanam P., et al. PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine 2015; 50 297-305. doi: 10.1007/s12020-015-0689-4. Cross Ref Medline Google Scholar.
98. Isidori A.M., et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. Journal of Clinical Endocrinology and Metabolism 2006; 91 371-377. doi: 10.1210/jc.2005-1542. Cross Ref Medline Web of Science Google Scholar.
99. de Bruin C., et al. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Reviews in Endocrine & Metabolic Disorders 2009; 10 91-102. doi: 10.1007/s11154-008-9082-4. Cross Ref Medline Web of Science Google Scholar.
100. Minniti G., Gilbert DC & Brada M. Modern techniques for pituitary radiotherapy. Reviews in Endocrine & Metabolic Disorders 2009; 10 135-144. doi: 10.1007/s11154-008-9106-0. Cross Ref Medline Web of Science Google Scholar.
101. Castinetti F., et al. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nature Reviews. Endocrinology 2010; 6 214-223. doi: 10.1038/ nrendo.2010.4. Cross Ref Medline Google Scholar.
102. Valassi E.,et al. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome. Clinical Endocrinology 2012; 77 735-742. doi: 10.1111/ j.1365-2265.2012.04424.x. Cross Ref Medline Google Scholar.
103. Xu Y., et al. The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias. World Journal of Surgery 2013; 37 1626-1632. doi: 10.1007/s00268-013-2059-9. Cross Ref Medline Google Scholar.
104. Albiger N.M. et al. An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a singlecentre experience. Clinical Endocrinology 2015; 82 808-815. doi: 10.1111/cen.12763. Cross Ref Medline Google Scholar.
105. Li J & Yang CH. Diagnosis and treatment of adrenocorticotrophic hormone-independent macronodular adrenocortical hyperplasia: a report of 23 cases in a single center. Experimental and Therapeutic Medicine 2015; 9(2): 507-512. doi: 10.3892/etm.2014.2115 Google Scholar.
106. Debillon E., et al. Unilateral adrenalectomy as a first-line treatment of Cushing's syndrome in patients with primary bilateral macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2015; 100 4417-4424. doi: 10.1210/jc.2015-2662. Cross Ref Medline Google Scholar.
107. Vezzosi D., et al. Hormonal, radiological, NP-59 scintigraphy and pathological correlations in patients with Cushing's syndrome due to Primary Pigmented Nodular Adrenocortical Disease (PPNAD). Journal of Clinical Endocrinology and Metabolism 2015; 100 4332-4338. doi: 10.1210/jc.2015-2174. Cross Ref Medline Google Scholar
108. O'Riordain D.S., Farley D.R., Young W.F J.R., Grant C.S., van Heerden J.A. Long-term outcome of bilateral adrenalectomy in patients with Cushing's syndrome. Surgery. 1994; 116: 1088-1093; discussion 1093-1094. Google Scholar. PubMed.
109. Hawn M.T., Cook D., Deveney C., Sheppard B.C. Quality of life after laparoscopic bilateral adrenalectomy for Cushing's disease. Surgery. 2002; 132: 1064-1068; discussion 1068-1069. Google Scholar. Cross Ref. PubMed.
110. Smith P.W., Turza K.C., Carter C.O., Vance M.L., Laws E.R., Hanks J.B. Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg. 2009 Jun; 208(6): 1059-64. doi: 10.1016/j.jamcollsurg.2009.02.054. Google Scholar. Cross Ref. PubMed.
111. Chow J.T., Thompson G.B., Grant C.S., Farley D.R., Richards M.L., Young W.F Jr. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf). 2008 Apr; 68(4): 513-519. DOI: 10.1111/j.1365-2265.2007.03082.x Google Scholar. Cross Ref. PubMed.
112. Colao A., Pivonello R., Spiezia S., et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999 Aug; 84(8): 2664-2672. DOI: 10.1210/jcem.84.8.5896 Google Scholar. PubMed.
113. Dekkers O.M., Biermasz N.R., Pereira A.M., et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007 Mar; 92(3): 976-981. DOI: 10.1210/jc.2006-2112 Google Scholar. Cross Ref. PubMed
114. Webb S.M., Badia X., Barahona M.J., et al. Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol. 2008 May; 158(5): 623-630. doi: 10.1530/EJE-07-0762. Google Scholar. Cross Ref. PubMed.
115. Barahona M.J., Resmini E., Viladés D., et al. Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab. 2013 Mar; 98(3): 1093-1099. doi: 10.1210/jc.2012-3547. Google Scholar. Cross Ref. PubMed № 05 (160) may 2018 GYNECOLOGY
116. Barahona M.J., Sucunza N., Resmini E., et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab. 2009 Sep; 94(9): 3365-3371. DOI: 10.1210/jc.2009-0766 Google Scholar. Cross Ref. PubMed.
117. Thompson S.K., Hayman A.V., Ludlam W.H., Deveney C.W., Loriaux D.L., Sheppard B.C. Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann Surg. 2007 May; 245(5): 790-794. DOI: 10.1097/01.sla.0000251578.03883.2f Google Scholar. Cross Ref. PubMed.
118. Arlt W., Allolio B. Adrenal insufficiency. Lancet. 2003; 361: 1881-1893. DOI: 10.1016/S0140-6736(03)13492-7 Google Scholar. Cross Ref. PubMed.
119. Hahner S., Loeffler M., Bleicken B., et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol. 2010 Mar; 162(3): 597-602. doi: 10.1530/EJE-09-0884. Google Scholar. Cross Ref. PubMed.
120. Flemming T.G., Kristensen L.O. Quality of self-care in patients on replacement therapy with hydrocortisone. J Intern Med. 1999 Nov; 246(5): 497-501. https://doi.org/10.1046/j.1365-2796.1999.00538.x Google Scholar. Cross Ref. PubMed.
121. Assié G., Bahurel H., Coste J., et al. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab. 2007 Jan; 92(1): 172-179. DOI: 10.1210/jc.2006-1328 Google Scholar. Cross Ref. PubMed.
122. Pereira M.A., Halpern A., Salgado L.R., et al. A study of patients with Nelson's syndrome. Clin Endocrinol (Oxf). 1998 Oct; 49(4): 533-539. DOI: 10.1046/j.1365-2265.1998.00578.x Google Scholar. Cross Ref. PubMed.
123. Thomas C.G J.R., Smith A.T., Benson M., Griffith J. Nelson's syndrome after Cushing's disease in childhood: a continuing problem. Surgery. 1984 Dec; 96(6): 1067-1077. Google Scholar. PubMed.
124. McCance D.R., Russell C.F., Kennedy T.L., Hadden D.R., Kennedy L., Atkinson A.B. Bilateral adrenalectomy: low mortality and morbidity in Cushing's disease. Clin Endocrinol (Oxf). 1993 Sep; 39(3): 315-321. https://doi.org/10.1111/j.1365-2265.1993.tb02371.x Google Scholar. Cross Ref. PubMed.
125. Barnett A.H., Livesey J.H., Friday K., Donald R.A., Espiner E.A. Comparison of preoperative and postoperative ACTH concentrations after bilateral adrenalectomy in Cushing's disease. Clin Endocrinol (Oxf). 1983 Mar; 18(3): 301-305. https://doi. org/10.1111/j.1365-2265.1983.tb03215.x Google Scholar. Cross Ref. PubMed.
126. Gil-Cdrdenas A., Cordon C.C., Gamino R., et al. Laparoscopic adrenalectomy: lessons learned from an initial series of 100 patients. Surg Endosc. 2008 Apr; 22(4): 991-994. DOI: 10.1007/s00464-007-9556-6 Google Scholar. Cross Ref. PubMed.
127. Kemink L., Pieters G., Hermus A., Smals A., Kloppenborg P. Patient's age is a simple predictive factor for the development of Nelson's syndrome after total adrenalectomy for Cushing's disease. J Clin Endocrinol Metab. 1994 Sep; 79(3): 887-889. DOI: 10.1210/jcem.79.3.80773 77 Google Scholar. PubMed.
128. Jenkins P.J., Trainer P.J., Plowman P.N., et al. The longterm outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab. 1995 Jan; 80(1): 165-171. DOI: 10.1210/jcem.80.1.7829606 Google Scholar. PubMed.
129. Mauermann W.J., Sheehan J.P., Chernavvsky D.R., Laws E.R., Steiner L., Vance M.L. Gamma knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy. J Neurosurg. 2007 Jun; 106(6): 988-993. DOI: 10.3171/ jns.2007.106.6.988 Google Scholar. Cross Ref. PubMed.
130. Moore T.J., Dluhy R.G., Williams G.H., Cain J.P. Nelson's syndrome: frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med. 1976 Dec; 85(6): 731-734. Google Scholar. Cross Ref. PubMed.
131. Sonino N., Zielezny M., Fava G.A., Fallo F., Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab. 1996 Jul; 81(7): 2647-2652. DOI: 10.1210/jcem.81.7.8675592 Google Scholar. PubMed.
132. Lumachi F., Ermani M., Basso S.M., et al. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg. 2005 Oct; 71(10): 864-869. [PubMed]
133. Letevernier E., Peyrard S., Amar L., et al. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens. 2008 Sep; 26(9): 1816-1823. doi: 10.1097/HJH.0b013e3283060f0c [PubMed]
134. Young W.F., J.R., Klee GG. Primary Aldosteronism. Diagnostic evaluation. Endocrinol Metabol Clin North Am. 1988 Jun; 17(2): 367-399. [PubMed]
135. Celen O., O'Brien M.J., Melby J.C., Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg. 1996 Jun; 131(6): 646-50. doi: 10.1001/archsurg.1996.01430180072015. [PubMed]
136. Obara T., Ito Y., Okamoto T., et al. Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery. 1992 Dec; 112(6): 987-993. [PubMed]
137. Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006; 1: 1039-1045. doi: 10.2215/CJN.01060306 [PubMed]
138. Zarnegar R., Young W.F., J.R., Lee J., et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg. 2008 Mar; 247(3): 511-518. doi: 10.1097/SLA.0b013e318165c075. [PubMed]
139. National high Blood Pressure Education Program. Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; 2003.
140. Sawka A.M., Young W.F., J.R., Thompson G.B., et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Int Med. 2001 Aug; 135(4): 258-261. DOI: 10.7326/0003-4819-135-4200108210-00010 [PubMed]
Рецензия
Для цитирования:
Киселева ТП, Чжен ТР, Торосян МР. Двусторонняя адреналэктомия в XXI веке, ее роль при гиперкортицизме? (обзор литературы). Уральский медицинский журнал. 2018;(5):78-91. https://doi.org/10.25694/URMJ.2018.04.074
For citation:
Kiseleva TP, Chzhen TR, Torosyan MR. Bilateral adrenalectomy in the 21st century, its role in hypercorticolism? (review of literature. Ural Medical Journal. 2018;(5):78-91. (In Russ.) https://doi.org/10.25694/URMJ.2018.04.074
Просмотров:
155
Послать статью по эл. почте 